Intelligent Bio Solutions (INBS) announced the receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under its new strategic manufacturing partnership with Syrma Johari MedTech .The shipment marks a significant step in scaling the Company’s production capacity and validates the operational and financial benefits of the collaboration announced in December 2025. The readers are now being deployed across key customer verticals, including construction, transportation and logistics, and manufacturing, throughout the U.K. and Europe, supporting growing commercial demand and expanding the Company’s installed base ahead of planned entry into the U.S. market, beyond the Forensic Use Only category, later this year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions announces partnership with Bouygues UK
- Intelligent Bio Solutions reports Q2 EPS ($2.82) vs. ($4.96) last year
- Intelligent Bio Solutions reports preliminary Q2 revenue $2.01M
- Intelligent Bio Solutions Launches Codeine Screening Clinical Program
- Intelligent Bio Solutions initiates additional studies for FDA 510k submission
